Management of myasthenia gravis

Seminars in Neurology

Volumn 24, Issue 1, 2004, Pages 41-48

  Saperstein, David S ^a   Barohn, Richard J ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Immunosuppressant; IVIg; Myasthenia gravis; Plasmapheresis; Thymectomy

Indexed keywords

AZATHIOPRINE; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; HYOSCYAMINE; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; MUSCLE SPECIFIC TYROSINE KINASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEOSTIGMINE; PREDNISONE; PYRIDOSTIGMINE; RITUXIMAB; TACROLIMUS; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ANEMIA; ANOREXIA; BONE MARROW SUPPRESSION; CANCER; CHILL; CORTICOSTEROID THERAPY; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG SAFETY; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HEADACHE; HEMORRHAGIC CYSTITIS; HIRSUTISM; HUMAN; HYPERTENSION; IMMUNOMODULATION; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; MOON FACE; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NAUSEA; NEPHROTOXICITY; OBESITY; OSTEOPENIA; OSTEOPOROSIS; PARESTHESIA; PLASMAPHERESIS; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SIDE EFFECT; THYMECTOMY; TREMOR; VERTIGO; VOMITING; WEIGHT GAIN;

CHOLINESTERASE INHIBITORS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION; PLASMAPHERESIS; THYMECTOMY;

EID: 3042544387     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-829586     Document Type: Review

References (75)

1. Berrouschot J, Baumann I, Kalischewski P, Sterker M, Schneider D. Therapy of myasthenic crisis. Crit Care Med 1997;25:1228-1235
2. Mayer SA, Thomas CE. Therapy of myasthenic crisis. Crit Care Med 1998;26:1136-1137
3. Tindall RSA. Humoral immunity in myasthenia gravis: effect of steroids and thymectomy. Neurology 1980;30:554-557
4. Warmolts JR, Engel WK. Benefit from alternate-day prednisone in myasthenia gravis. N Engl J Med 1972;286:17-20
5. Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984;15:291-298
6. Johns TR. Long-term corticosteroid treatment of myasthenia gravis. Ann N Y Acad Sci 1984;505:568-583
7. Miller RG, Milner-Brown S, Mirka A. Prednisone-induced worsening of neuromuscular function in myasthenia gravis. Neurology 1986;36:729-732
8. Seybold ME, Drachman DB. Gradually increasing doses of prednisone in myasthenia gravis: reducing the hazards of treatment. N Engl J Med 1974;290:81-84
9. Saperstein DS, Amato AA, Katz JS, Barohn RJ. Immune mediated polyneuropathies. In: Pourmand R, ed. Neuromuscular Diseases: Expert Clinicians' Views. Boston: Butterworth-Heinemann; 2001:135-198
10. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998;339:292-299
11. Mantegazza R, Antozzi C, Peluchitte D, Sghirlanzoni A, Cornelio F. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol 1988;235:449-453
12. Myasthenia Gravis Clinical Study Group. A randomized clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. J Neurol Neurosurg Psychiatry 1993;53:1157-1163
13. Matell G. Immunosuppressive drugs: azathioprine in the treatment of myasthenia gravis. Ann N Y Acad Sci 1987;505: 588-594
14. Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV. Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis. Neurology 1988;38: 258-261
15. Mertens HG, Hertel P, Reuther P, Ricker K. Effect of immunosuppressive drugs (Azathioprine). Ann N Y Acad Sci 1981;337:691-699
16. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998;50:1778-1783
17. Kissel JT, Levy RJ, Mendell JR, Griggs RC. Azathioprine toxicity in neuromuscular disease. Neurology 1986;36: 35-39
18. Herrlinger U, Weller M, Dichgans J, Melms A. Association of primary central nervous system lymphoma with long-term azathioprine therapy for myasthenia gravis. Ann Neurol 2000; 47:682-683
19. Tindall RSA, Phillips JT, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cydosporine in myasthenia gravis. Ann N Y Acad Sci 1993;681:539-551
20. Tindall RSA, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987;316:719-724
21. Ciafaloni E, Nikhar NK, Massey JM, Sanders DB. Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology 2000;55:448-450
22. Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 2001;56:97-99
23. Chaudhry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001;56:94-96
24. Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003;61:1438-1440
25. Meriggioli MN, Rowin J, Richman JG, Leurgans S. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann N Y Acad Sci 2003;998: 494-499
26. Haberal M, Karakayali H, Emiroglu R, Basaran O, Moray G, Bilgin N. Malignant tumors after organ transplantation. Artif Organs 2002;26:778-781
27. Perez MC, Buot WL, Mercado-Danguilan C, Bagabaldo ZG, Renales LD. Stable remissions in myasthenia gravis. Neurology 1981;31:32-37
28. De Feo LG, Schottlender J, Martelli NA, Molfino NA. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve 2002;26:31-36
29. Drachman DB, Jones RJ, Brodsky RA. Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamide. Ann Neurol 2003;53:29-34
30. Dau PC, Lindstrom JM, Cassel CK, Denys EH, Shev EE, Spitler LE. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. N Engl J Med 1977;297:1134-1140
31. Arsura E. Experience with intravenous immunoglobulin in myasthenia gravis. Clin Immunol Immunopathol 1989;53: S170-S179
32. Fateh-Moghadam A, Wick M, Besinger U, Geursen RG. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984;1:848-849
33. Gajdos P, Outin H, Elkharrat D, et al. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984;1:406-407
34. Cosi V, Lombardi M, Piccolo G, Erbetta A. Treatment of myasthenia gravis with high-dose intravenous immunoglobulin. Acta Neurol Scand 1991;84:81-84
35. Dalakas MC. Experience with IVIg in the treatment of patients with myasthenia gravis. Neurology 1997;48(suppl 5): S64-S69
36. Achiron A, Barak Y, Miron S, Sarova-Pinhas I. Immunoglobulin treatment in refractory myasthenia gravis. Muscle Nerve 2000;23:551-555
37. Jongen JL, van Doorn PA, van der Meche FG. High-dose intravenous immunoglobulin therapy for myasthenia gravis. J Neurol 1998;245:26-31
38. Liblau R, Gajdos P, Bustarret FA, et al. Intravenous gammaglobulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies. J Clin Immunol 1991;11:128-131
39. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C, for the Myasthenia Gravis Clinical Study Group. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 1997;41:789-796
40. Qureshi AI, Choudhry MA, Akbar MS, et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999;52:629-632
41. Stricker RB, Kwiatkowska BJ, Habis JA, Kiprov DD. Myasthenic crisis: response to plasmapheresis following failure of intravenous gamma-globulin. Arch Neurol 1993;50:837-840
42. Wolfe GI, Barohn RJ, Foster BM, et al. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve 2002;26:549-552
43. Tan E, Hajinazarian M, Bay W, Neff J, Mendell JR. Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol 1993;50:137-139
44. Steg RE, Lefkowitz DM. Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis. Neurology 1994;44:1180-1181
45. Caress JB, Cartwright MS, Donofrio PD, Peacock JE Jr. The clinical features of 16 cases of stroke associated with administration of IVIG. Neurology 2003;60:1822-1824
46. Blalock A, Mason MF, Morgan HJ, et al. Myasthenia gravis and tumors of the thymic region. Report of a case in which the tumor was removed. Ann Surg 1939;110:544-561
47. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55: 7-15
48. Mantegazza R, Baggi F, Antozzi C, et al. Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann N Y Acad Sci 2003;998:413-423
49. Perlo VP, Arnason B, Poskanzer D, et al. The role of thymectomy in the treatment of myasthenia gravis. Ann N Y Acad Sci 1971;183:308-315
50. Rodriguez M, Gomez MR, Howard FM Jr, Taylor WF. Myasthenia gravis in children: long-term follow-up. Ann Neurol 1983;13:504-510
51. Mulder DG, Graves M, Herrmann C. Thymectomy for myasthenia gravis: recent observation and comparisons with past experience. Ann Thorac Surg 1989;48:551-555
52. Lanska DJ. Diagnosis of thymoma in myasthenics using antistriated muscle antibodies: predictive value and gain in diagnostic certainty. Neurology 1991;41:520-524
53. Schumm F, Wiethölter H, Fateh-Moghadam A, Dichgans J. Thymectomy in myasthenia with pure ocular symptoms. J Neurol Neurosurg Psychiatry 1985;48:332-337
54. Lanska DJ. Indications for thymectomy in myasthenia gravis. Neurology 1990;40:1828-1829
55. Grob D, Asura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci 1987;505:472-499
56. McQuillen MP, Leone MG. A treatment carol: thymectomy revisited. Neurology 1977;27:1103-1106
57. Wolfe GI, Kaminski HJ, Jaretzki A III, Swan A, Newsom-Davis J. Development of a thymectomy trial in nonthymomatous myasthenia gravis patients receiving immunosuppressive therapy. Ann N Y Acad Sci 2003;998:473-480
58. Monden Y, Nakahara K, Kagotani K, et al. Effects of preoperative duration of symptoms on patients with myasthenia gravis. Ann Thorac Surg 1984;38:287-291
59. DeFilippi VJ, Richman DP, Ferguson MK. Transcervical thymectomy for myasthenia gravis. Ann Thorac Surg 1994; 57:194-197
60. Younger DS, Jaretzki A III, Penn AS, et al. Maximum thymectomy for myasthenia gravis. Ann N Y Acad Sci 1987; 505:832-835
61. Papatestas AE, Genkins G, Kornfeld P, Horowitz S, Kark AE. Transcervical thymectomy in myasthenia gravis. Surg Gynecol Obstet 1975;140:535-540
62. Cooper JD, Al-Jilaihawa AN, Pearson FG, Humphrey HE. An improved technique to facilitate transcervical thymectomy for myasthenia gravis. Ann Thorac Surg 1988;45:242-247
63. Yim AP, Kay RL, Ho JK. Video-assisted thoracoscopic thymectomy for myasthenia gravis. Chest 1995;108:1440-1443
64. Sabbagh MN, Garza JJS, Patten B. Thoracoscopic thymectomy in patients with myasthenia gravis. Muscle Nerve 1995; 18:1475-1477
65. Mack MJ, Landreneau RJ, Yim AP, Hazelrigg SR, Scruggs GR. Results of video-assisted thymectomy in patients with myasthenia gravis. J Thorac Cardiovasc Surg 1996;112:1352-1359
66. Batra P, Herrmann C Jr, Mulder D. Mediastinal imaging in myasthenia gravis: correlation of chest radiography, CT, MR, and surgical findings. AJR Am J Roentgenol 1987;148:515-519
67. Nations SP, Wolfe GI, Amato AA, Jackson C, Bryan WW, Barohn RJ. Myasthenia gravis developing after removal of thymoma. J Child Neurol 1997;12:133
68. Yoshikawa H, Mabuchi K, Yasukawa Y, Takamori M, Yamada M. Low-dose tacrolimus for intractable myasthenia gravis. J Clin Neurosci 2002;9:627-628
69. Evoli A, Di Schino C, Marsili F, Punzi C. Successful treatment of myasthenia gravis with tacrolimus. Muscle Nerve 2002;25:111-114
70. De Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000;35:333-346
71. Wylam ME, Anderson PM, Kuntz NL, Rodriguez V. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. J Pediatr 2003;143:674-677
72. Zaja F, Russo D, Fuga G, Perella G, Baccarani M. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 2000;55:1062-1063
73. Scuderi F, Marino M, Colonna L, et al. Anti-P110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement. Lab Invest 2002;82:1139-1146
74. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-368
75. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003;60:1978-1980